Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
, Encourages Investors with Losses to Contact Firm - EconoTimes)
NEW YORK, Sept. 29, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global shareholder rights litigation firm, has opened an investigation on behalf of investors in Zosano Pharma Corp (ZSAN). The investigation focuses on whether Zosano and certain of its executives and directors made false statements to investors about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.
Investors who own Zosano stock are encouraged to contact Scott + Scott at (646)-582-0121 or email [email protected] to discuss their legal rights.
Scott + Scott, LLP is investigating potential violations of the federal securities laws in connection with the Company’s January 27, 2015 Initial Public Offering (“IPO”). In particular, the firm is investigating whether Zosano and certain of its executives and directors made false statements and omitted material information about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.
What You Can Do
If you purchased shares of Zosano, you may have legal claims against the Company. If you wish to discuss the investigation, or have questions about your legal rights, please contact Joseph Halloran, Esq. by telephone at (646)-582-0121 or by email at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott, Attorneys at Law, LLP has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio. Please visit www.scott-scott.com for more information about the firm.
Contact Scott + Scott, Attorneys at Law, LLP Joseph Halloran 646.582.0121 [email protected]
